MCID: ANG054
MIFTS: 65

Angina Pectoris

Categories: Cardiovascular diseases, Rare diseases

Aliases & Classifications for Angina Pectoris

MalaCards integrated aliases for Angina Pectoris:

Name: Angina Pectoris 40 36 37 17 32
Prinzmetal's Variant Angina 12 73 20 70
Prinzmetal Angina 12 20 15
Variant Angina 12 20 54
Coronary Artery Vasospasm 20 70
Angina Pectoris, Variant 44 70
Prinzmetal's Angina 12 17
Angina Inversa 12 20
Angina 42 62
Variant Angina Pectoris 12
Vasospastic Angina 20

Classifications:



External Ids:

Disease Ontology 12 DOID:0111151
KEGG 36 H01632
MeSH 44 D000788
ICD10 32 I20 I20.1 I20.9
UMLS 70 C0002963 C0010073 C2931193

Summaries for Angina Pectoris

GARD : 20 Prinzmetal's variant angina (PVA) is characterized by recurrent episodes of chest pain ( angina ) that usually occur when a person is at rest, between midnight and early morning. "Typical" angina, by contrast, is often triggered by physical exertion or emotional stress. Episodes of PVA can be very painful, and may last from several minutes to thirty minutes. In some cases the pain may spread from the chest to the head, shoulder, or arm. The pain associated with PVA is caused by a spasm in the arteries that supply blood to the heart muscle ( coronary arteries ). This results in an obstruction of blood flow. In some people, persistent spasms increase the risk for serious complications such as a life-threatening arrhythmia or heart attack. PVA most commonly occurs in people who smoke and people who have high cholesterol or high blood pressure. In many cases it occurs for unknown reasons in otherwise healthy people. In some cases it may be triggered by alcohol withdrawal, stress, exposure to cold, certain medications, or use of stimulants such as cocaine. The diagnosis of PVA involves findings on an electrocardiogram, evidence of the spasms on angiogram, and relief of sudden symptoms with medicines called nitrates. Treatment during an episode to relieve pain and shorten its duration involves sublingual nitroglycerin (a nitrate). Treatment to reduce the frequency of episodes and possibly reduce the risk of serious complications involves calcium channel blockers or long-acting nitrates. For people with PVA who smoke, quitting smoking can lead to a significant decrease in the frequency of episodes. While most people with PVA do not experience serious complications, it is a chronic condition that needs to be monitored over time.

MalaCards based summary : Angina Pectoris, also known as prinzmetal's variant angina, is related to coronary thrombosis and coronary heart disease 1, and has symptoms including other and unspecified angina pectoris An important gene associated with Angina Pectoris is EDN1 (Endothelin 1), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Toll-like Receptor Signaling Pathway. The drugs Chromium and Cobalt have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and spinal cord, and related phenotypes are cardiovascular system and behavior/neurological

Disease Ontology : 12 A coronary artery vasospasm characterized by spasms of the coronary arteries that occur while at rest, generally late at night or early in the morning, resulting in severe chest pain with preserved exercise capacity.

MedlinePlus : 42 Angina is chest pain or discomfort you feel when there is not enough blood flow to your heart muscle. Your heart muscle needs the oxygen that the blood carries. Angina may feel like pressure or a squeezing pain in your chest. It may feel like indigestion. You may also feel pain in your shoulders, arms, neck, jaw, or back. Angina is a symptom of coronary artery disease (CAD), the most common heart disease. CAD happens when a sticky substance called plaque builds up in the arteries that supply blood to the heart, reducing blood flow. There are three types of angina: Stable angina is the most common type. It happens when the heart is working harder than usual. Stable angina has a regular pattern. Rest and medicines usually help. Unstable angina is the most dangerous. It does not follow a pattern and can happen without physical exertion. It does not go away with rest or medicine. It is a sign that you could have a heart attack soon. Variant angina is rare. It happens when you are resting. Medicines can help. Not all chest pain or discomfort is angina. If you have chest pain, you should see your health care provider. NIH: National Heart, Lung, and Blood Institute

KEGG : 36 Angina pectoris is defined as cardiac-induced pain arising from a lack of myocardial oxygen. "Angina" is used to describe clinical symptoms such as discomfort in the chest, jaw, shoulder, back, or arms that are induced by physical exertion or emotional stress and subside with rest or treatment with nitroglycerin. Angina is clinically classified into stable angina (SA) and unstable angina (UA). SA is a chronic medical condition while UA is an acute coronary syndrome. Among the causes of angina pectoris, the most common is coronary artery disease (CAD). At the cellular level, angina pectoris is a result of increased myocardial oxygen demand or decreased myocardial oxygen supply.

PubMed Health : 62 About angina: Angina (an-JI-nuh or AN-juh-nuh) is chest pain or discomfort that occurs if an area of your heart muscle doesn't get enough oxygen-rich blood. Angina may feel like pressure or squeezing in your chest. The pain also can occur in your shoulders, arms, neck, jaw, or back. Angina pain may even feel like indigestion. Angina isn't a disease; it's a symptom of an underlying heart problem. Angina usually is a symptom of coronary heart disease (CHD). CHD is the most common type of heart disease in adults. It occurs if a waxy substance called plaque (plak) builds up on the inner walls of your coronary arteries. These arteries carry oxygen-rich blood to your heart.

Wikipedia : 73 Angina, also known as angina pectoris, is chest pain or pressure, usually due to insufficient blood flow... more...

Related Diseases for Angina Pectoris

Diseases related to Angina Pectoris via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 956)
# Related Disease Score Top Affiliating Genes
1 coronary thrombosis 31.4 PLAT F3 CRP
2 coronary heart disease 1 31.3 INS CRP APOA1 ADIPOQ ACE
3 intermittent claudication 31.3 IL6 CRP ACE
4 cardiogenic shock 31.1 PLAT NPPB IL6
5 subclavian steal syndrome 30.9 F3 CRP
6 cellulitis 30.8 INS IL6 F3 CRP
7 syphilis 30.8 IL6 CRP ACE
8 raynaud disease 30.8 EDN1 CRP ACE
9 first-degree atrioventricular block 30.6 NPPB CRP ACE
10 mediastinitis 30.6 INS F3 CRP
11 hypercholesterolemia, familial, 1 30.6 NOS3 INS CRP APOA1 ACE
12 atrial fibrillation 30.6 PLAT NPPB CRP ACE
13 diabetic neuropathy 30.5 INS ICAM1 ACE
14 kawasaki disease 30.5 NPPB IL6 CRP
15 orthostatic intolerance 30.5 NOS3 EDN1 ACE
16 ileus 30.5 INS IL6 CRP
17 atrioventricular block 30.5 TNNI3 PIK3C2A NPPB ACE
18 aortic valve insufficiency 30.5 TNNI3 NPPB F3 CRP ACE
19 anterolateral myocardial infarction 30.5 PLAT NPPB ACE
20 granulomatous angiitis 30.5 CRP ACE
21 takayasu arteritis 30.5 IL6 ICAM1 EDN1 CRP
22 peripheral vascular disease 30.5 PLAT KNG1 IL6 F3 CRP APOA1
23 paralytic ileus 30.4 INS CRP
24 lipid metabolism disorder 30.4 INS IL6 CRP APOA1 ADIPOQ ACE
25 eisenmenger syndrome 30.4 PLAT EDN1
26 mitral valve stenosis 30.4 NPPB F3 EDN1 CRP ACE
27 heart aneurysm 30.4 IL6 CRP ACE
28 heart valve disease 30.4 TNNI3 NPPB CRP ACE
29 hemopericardium 30.4 TNNI3 F3 CRP
30 coronary stenosis 30.3 TNNI3 PIK3C2A NPPB IL6 ICAM1 CRP
31 chronic urticaria 30.3 IL6 CRP ACE
32 bronchiolitis 30.3 IL6 ICAM1 CRP
33 nodular goiter 30.3 IL6 ICAM1 CRP
34 proteasome-associated autoinflammatory syndrome 1 30.3 INS IL6 ICAM1 CRP ADIPOQ
35 gallbladder disease 30.3 INS CRP APOA1
36 cerebral atherosclerosis 30.3 CRP APOA1 ACE
37 thrombocytosis 30.3 IL6 F3 CRP
38 thrombophlebitis 30.3 PLAT F3 CRP
39 complex regional pain syndrome 30.3 IL6 EDN1 ACE
40 toxic shock syndrome 30.3 IL6 F3 CRP
41 cardiac rupture 30.3 PLAT CRP
42 moyamoya disease 1 30.3 PLAT F3 CRP
43 antiphospholipid syndrome 30.3 PLAT F3 CRP
44 synovitis 30.2 IL6 ICAM1 CRP
45 right bundle branch block 30.2 TNNI3 NPPB ACE
46 constrictive pericarditis 30.2 TNNI3 NPPB CRP ACE
47 myocardial stunning 30.2 TNNI3 KNG1 EDN1 ACE
48 exanthem 30.2 PIK3C2A IL6 F3 CRP ACE
49 peripheral nervous system disease 30.2 KNG1 INS IL6 CRP ACE
50 aortic valve disease 2 30.2 TNNI3 NPPB CRP ACE

Comorbidity relations with Angina Pectoris via Phenotypic Disease Network (PDN):


Esophagitis Hypertension, Essential
Intermediate Coronary Syndrome Mitral Valve Disease

Graphical network of the top 20 diseases related to Angina Pectoris:



Diseases related to Angina Pectoris

Symptoms & Phenotypes for Angina Pectoris

UMLS symptoms related to Angina Pectoris:


angina pectoris; other and unspecified angina pectoris

MGI Mouse Phenotypes related to Angina Pectoris:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.33 ACE ADIPOQ APOA1 CRP EDN1 F3
2 behavior/neurological MP:0005386 10.22 ACE ADIPOQ F3 HTR1B IL6 INS
3 growth/size/body region MP:0005378 10.18 ACE ADIPOQ EDN1 F3 HTR1B ICAM1
4 cellular MP:0005384 10.17 ADIPOQ APOA1 F3 HTR1B ICAM1 IL6
5 homeostasis/metabolism MP:0005376 10.17 ACE ADIPOQ APOA1 CRP EDN1 F3
6 endocrine/exocrine gland MP:0005379 10.1 ACE ADIPOQ APOA1 EDN1 HTR1B ICAM1
7 mortality/aging MP:0010768 10.07 ACE ADIPOQ EDN1 F3 HTR1B ICAM1
8 adipose tissue MP:0005375 10.04 ACE ADIPOQ HTR1B IL6 INS NOS3
9 muscle MP:0005369 9.9 ADIPOQ EDN1 F3 HTR1B ICAM1 IL6
10 renal/urinary system MP:0005367 9.5 ACE ADIPOQ EDN1 IL6 INS NOS3
11 respiratory system MP:0005388 9.17 ADIPOQ F3 IL6 MB NOS3 PLAT

Drugs & Therapeutics for Angina Pectoris

PubMed Health treatment related to Angina Pectoris: 62

Treatments for angina include lifestyle changes, medicines, medical procedures, cardiac rehabilitation (rehab), and other therapies . The main goals of treatment are to: Reduce pain and discomfort and how often it occurs Prevent or lower your risk for heart attack and death by treating your underlying heart condition Lifestyle changes and medicines may be the only treatments needed if your symptoms are mild and aren't getting worse. If lifestyle changes and medicines don't control angina , you may need medical procedures or cardiac rehab . Unstable angina is an emergency condition that requires treatment in a hospital.

Drugs for Angina Pectoris (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 300)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Chromium Approved Phase 4 7440-47-3 27668
2
Cobalt Approved, Experimental Phase 4 7440-48-4 104729
3
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
4
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
5
Pantoprazole Approved Phase 4 102625-70-7 4679
6
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
7
Bisoprolol Approved Phase 4 66722-44-9 2405
8
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
9
Ephedrine Approved Phase 4 299-42-3 9294
10
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
11
Pseudoephedrine Approved Phase 4 90-82-4 7028
12
Molsidomine Approved, Investigational Phase 4 25717-80-0
13
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
14
Amlodipine Approved Phase 4 88150-42-9 2162
15
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
16
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
17
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
18
Methyltestosterone Approved Phase 4 58-18-4 6010
19
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
20
Testosterone enanthate Approved Phase 4 315-37-7 9416
21
Testosterone Approved, Investigational Phase 4 58-22-0 6013
22
Ramipril Approved Phase 4 87333-19-5 5362129
23
Liraglutide Approved Phase 4 204656-20-2 44147092
24
Atenolol Approved Phase 4 29122-68-7 2249
25
Pravastatin Approved Phase 4 81093-37-0 54687
26
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
27
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
28
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
29
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
30
Abciximab Approved Phase 4 143653-53-6
31
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
32
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
33
Fondaparinux Approved, Investigational Phase 4 104993-28-4
34
Empagliflozin Approved Phase 4 864070-44-0
35
Cangrelor Approved Phase 4 163706-06-7 9854012
36
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
37
Polyestradiol phosphate Approved Phase 4 28014-46-2
38
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
39
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
40
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
41
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
42
Methoxyflurane Approved, Investigational, Vet_approved Phase 4 76-38-0 4116
43
Morphine Approved, Investigational Phase 4 57-27-2 5288826
44
Edoxaban Approved Phase 4 480449-70-5
45
Metformin Approved Phase 4 657-24-9 14219 4091
46
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
47
Enoxaparin Approved Phase 4 9005-49-6 772
48
Nitric Oxide Approved Phase 4 10102-43-9 145068
49
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
50
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510

Interventional clinical trials:

(show top 50) (show all 794)
# Name Status NCT ID Phase Drugs
1 Ischemia In Hemodialysed Patients And Outcome: Ivabradine Versus Carvedilol. A Randomized, Double Blind Study Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
2 A Morbi-Mortality and Remodeling Study With Valsartan in Patients With Hypertension and Cardiovascular Disease Unknown status NCT00133328 Phase 4 valsartan
3 Efficacy Study of Atorvastatin to Treat Variant Angina Unknown status NCT00620204 Phase 4 atorvastatin
4 Effects of Long-term Vitamin C+E and Statin Therapy on Vasospasm Improvement and Regression of Atheroma in Patients With Variant Angina Unknown status NCT03228238 Phase 4 Vitamin C and Vitamin E;Statin;Standard medication for variant angina
5 Effect of Amlodipine Versus Amlodipine Combined With Atorvastatin on the Symptoms, Function, and Quality of Life in Patients With Coronary Vasospastic Angina Unknown status NCT03054467 Phase 4 Caduet 10Mg-20Mg Tablet;NorvasC® 10 mg Tablets
6 A Prospective, Single-center, Randomized Study to Evaluate the Effect of Sarpogrelate, a Selective Serotonin Receptor Antagonist, and High Dose Statin on the Reduction of Coronary Spasm in the Patients With Variant Angina Unknown status NCT01674686 Phase 4 Sarpogrelate;Atorvastatin
7 Impact of Paclitaxel-eluting Stent for Small Coronary Artery Disease Unknown status NCT00955214 Phase 4
8 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Based on Population Pharmacokinetics and Therapeutic Effect:A Randomized, Controlled Trial Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
9 A Prospective, Randomised, Open-labeled, Parallel Group Study to Assess the Efficacy and Safety of Low Dose Ticagrelor Compared With Standard Dose Ticagrelor in Patients With Unstable Angina Pectoris After Drug Eluting Stent Implantation Unknown status NCT03620760 Phase 4 Ticagrelor 90 mg;Ticagrelor 45 mg;Aspirin
10 A Randomized, Double-blind, Placebo-controlled Trial of Dan-shen Extract in Patients With Stable Angina Pectoris Unknown status NCT02870764 Phase 4 Dan-shen extract;Placebo
11 The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
12 To Evaluate the Efficacy and Safety of Xinnaoning Capsule in Treating Chronic Stable Angina Pectoris (Qi Stagnation and Blood Stasis Syndrome) : a Randomized, Double-blind, Parallel Controlled, Multi-center Clinical Study Unknown status NCT03914131 Phase 4 Xinnaoning Capsule
13 Efficacy and Safety of Salvianolate Injection in Elderly Patients With Unstable Angina Pectoris: a Parallel, Double Blind, Randomized, Controlled, Multi-center Trial. Unknown status NCT03037047 Phase 4 0.9% Sodium Chloride Injection;salvianolate injection
14 A Prospective, Multi-Center, Open Label, Randomized Controlled, Two Arm Study Evaluating Safety and Efficacy of the Permanent Polymer Zotarolimus Eluting Stent Resolute Integrity Compared to the Polymer Free Amphilimus Eluting Stent Cre8 Unknown status NCT02328898 Phase 4
15 Comparison of Low-dose Heparin Versus Standard Dose Heparin During Coronary Interventions (DEDICA Trial) Unknown status NCT01694459 Phase 4 Low-dose heparin;Standard dose heparin
16 Randomized Study on SCS for the Treatment of Refractory Angina Pectoris Unknown status NCT00121654 Phase 4
17 A Randomized, Double-Blind, Placebo-Controlled Trial for DaZhu Rhodiola Rosea Capsule in the Treatment of Coronary Artery Disease With Angina Pectoris Unknown status NCT03633890 Phase 4 DaZhu Rhodiola Rosea Capsule;DaZhu Rhodiola Rosea Simulation Capsule
18 Absorption and Pharmacokinetics of Nitroglycerin as a Tablet or in the Form of Rapidly Degradable Capsule in Young Healthy Unknown status NCT03777605 Phase 4 Nitroglycerin 0.4 MG
19 Effect of Vitamin C Infusion on Coronary Reperfusion Indexes Unknown status NCT01090895 Phase 4 Vitamin C;Placebo
20 Safety of Amiodarone and Ranolazine Together in Patients With Stable Angina Unknown status NCT01558830 Phase 4 ranolazine;placebo
21 A Comparative Study to Assess the Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment naïve Patients of Chronic Stable Angina. Unknown status NCT01397994 Phase 4 Nicorandil;Atenolol
22 Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina Unknown status NCT02284048 Phase 4 ticagrelor
23 Efficacy and Safety Study of Guanxin Shutong Capsule to Treat Chronic Stable Angina: A Randomised, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT02280850 Phase 4 Guanxin Shutong Capsule;Placebo Capsule;nitroglycerine
24 Research on the Clinical Effect of Xuefu Zhuyu Decoction in Treating Unstable Angina. Unknown status NCT03179618 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Xuefu Zhuyu Decoction
25 Research on the Clinical Effect of Gualou Xiebai Banxia Decoction Compounded With Danshen Decoction in Treating Unstable Angina. Unknown status NCT03179514 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Gualou Xiebai Banxia Decoction & Danshen Decoction
26 Research on the Clinical Effect of Effective Prescription in Treating Unstable Angina. Unknown status NCT03171597 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Xuefu Zhuyu Decoction;Gualou Xiebai Banxia Decoction & Danshen Decoction;Shuanghe Decoction
27 Research on the Clinical Effect of Shuanghe Decoction in Treating Unstable Angina. Unknown status NCT03179527 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Shuanghe Decoction
28 Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention Unknown status NCT03044964 Phase 4 Ranolazine;Placebo
29 Effect of Alirocumab(Proprotein Convertase Subtilisin/Kexin type9 Inhibitor) and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular Ultrasound Unknown status NCT03529253 Phase 4 Alirocumab 75 MG/ML [Praluent]+ Rosuvastatin 10mg/daily;Rosuvastatin calcium10mg
30 Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis Unknown status NCT01823185 Phase 4 clopidogrel;Ticagrelor or prasugrel
31 A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial Unknown status NCT02609698 Phase 4 3 months DAPT;6 months DAPT
32 Single-center Randomized Controlled Study of Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Randomized Controlled Trials Unknown status NCT01735227 Phase 4 omeprazole;Pantoprazole
33 A Pilot Study Exploring Efficacy and Safety of Amlodipine in the Stented Angina Patients Unknown status NCT01120327 Phase 4 Placebo;Amlodipine
34 Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI Unknown status NCT02012140 Phase 4 ticagrelor
35 TWice overnIght High-dose ranoLazIne Pretreatment for preventinG Myocardial iscHemic Damage in Patients With Stable Angina Undergoing percuTaneous Coronary Intervention Unknown status NCT01491061 Phase 4 Ranolazine;Placebo
36 Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation Unknown status NCT01162902 Phase 4 Diltiazem treated group;Bisoprolol treated group;Candesartan treated group
37 Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine) Unknown status NCT03486561 Phase 4 Ranolazine
38 Optical Coherence tOmography Based Edge and In-stent Vascular Response After a Novel bioDegradable Polymer sIrolimus-eLuting Stent in patIents With Non-ST Elevation acuTe Coronary sYndrome (NSTE ACS) Unknown status NCT02868203 Phase 4
39 Efficacy Study of Nicorandil on Neointima After Coronary Drug-eluting Stent Implantation in Patients With Diabetic Mellitus Unknown status NCT02328521 Phase 4 Nicorandil;nicorandil placebo
40 Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image Unknown status NCT01769482 Phase 4 Udenafil;placebo
41 Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization. Unknown status NCT02099617 Phase 4
42 A French, Multicentric, Randomized, Simple Blind, Superiority Study Comparing the Efficiency and the Safety at 24 Months of the Stent Titan2 Versus Bare Metal Stent in Cobalt-Chrome in All Comers Patients Among Which 40 % Present an ACS. Unknown status NCT01918150 Phase 4
43 The Safety and Efficacy of Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome Unknown status NCT01372839 Phase 4 Atorvastatin;Statin
44 Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly Unknown status NCT02317198 Phase 4 Clopidogrel;Ticagrelor or Prasugrel
45 Coronary Angioplasty in Octogenarians With Emergent Coronary Syndromes: The Octogenarians Study Unknown status NCT02126202 Phase 4
46 Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor . Unknown status NCT02032303 Phase 4 Ticagrelor loading;Prasugrel loading
47 Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel Unknown status NCT02032290 Phase 4 ticagrelor loading;Clopidogrel loading
48 Double-blind Parallel Placebo-controlled Study to Evaluate the Effect of Molsidomine on the Endothelial Dysfunction in Patients With Stable Angina Pectoris Undergoing a Percutaneous Coronary Intervention Completed NCT01363661 Phase 4 Coruno;Placebo
49 A Randomised, Open Label, Parallel Group, Multicentre, Phase IV Study on the Effect of 8 Weeks Succinate Metoprolol (Betaloc ZOK®) (95 - 190 mg) on Heart Rate in the Stable Angina Patients Completed NCT01213173 Phase 4 Succinate Metoprolol (Betaloc ZOK®);Succinate Metoprolol (Betaloc ZOK®)
50 Nebivolol for the Relief of Microvascular Angina in Women Completed NCT01665508 Phase 4 Nebivolol

Search NIH Clinical Center for Angina Pectoris

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Amlodipine
Amlodipine Besylate
Diltiazem
Diltiazem Hydrochloride
Diltiazem maleate
DITIAZ
Felodipine
Isradipine
Nicardipine
Nicardipine hydrochloride
Nifedipine
Nisoldipine
Verapamil
Verapamil hydrochloride

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Angina Pectoris cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: angina pectoris, variant

Genetic Tests for Angina Pectoris

Anatomical Context for Angina Pectoris

MalaCards organs/tissues related to Angina Pectoris:

40
Heart, Endothelial, Spinal Cord, Bone, Bone Marrow, Thyroid, Kidney

Publications for Angina Pectoris

Articles related to Angina Pectoris:

(show top 50) (show all 19617)
# Title Authors PMID Year
1
Acupoint for angina pectoris: A protocol for systematic review and meta-analysis. 42 61
33546012 2021
2
Efficacy and safety of Xuefu Zhuyu decoction combined with Western medicine for angina pectoris in coronary heart disease: A protocol for systematic review and meta-analysis. 61 42
33327236 2020
3
Effectiveness and safety of Yufengningxin for treating coronary heart disease angina: A protocol for a systematic review and meta-analysis. 42
33350791 2020
4
Endothelial nitric oxide synthase T-786C mutation, a reversible etiology of Prinzmetal's angina pectoris. 54 61
20211321 2010
5
Lipoprotein-associated phospholipase A2 (Lp-PLA2) - possible diagnostic and risk biomarker in chronic ischaemic heart disease. 61
33187461 2021
6
S100A1 is a sensitive and specific cardiac biomarker for early diagnosis and prognostic assessment of acute myocardial infarction measured by chemiluminescent immunoassay. 61
33476588 2021
7
Serial assessment of de novo coronary lesions after drug-coated balloon treatment analyzed by intravascular ultrasound: A comparison between acute coronary syndrome and stable angina pectoris. 61
33539851 2021
8
Effectiveness and Safety of Extracorporeal Shockwave Myocardial Revascularization in Patients With Refractory Angina Pectoris and Heart Failure. 61
33385348 2021
9
Simultaneous transaortic transcatheter aortic valve implantation and off-pump coronary artery bypass: An effective hybrid approach. 61
33491207 2021
10
Assessment of lateral costal artery with CT angiography: determination of prevalence and vessel length in the general population and its potential impact for coronary artery bypass grafting. 61
32965574 2021
11
Trans-ventricular catheter device-based closure of postmyocardial infarction ventricular septal defect following coronary artery bypass grafting: A staged hybrid approach. 61
33502796 2021
12
Utility of angiography-physiology coregistration maps during percutaneous coronary intervention in clinical practice. 61
32507942 2021
13
COVID-19-related arrhythmias and the possible effects of ranolazine. 61
33636586 2021
14
Kuanxiong aerosol inhibits apoptosis and attenuates isoproterenol-induced myocardial injury through the mitogen-activated protein kinase pathway. 61
33359915 2021
15
Sex-related differences in symptomatic patients with hypertrophic obstructive cardiomyopathy - Time for a new definition? 61
33359283 2021
16
Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications. 61
33226665 2021
17
Invasive aortic pulse pressure is not superior to cuff pulse pressure in cardiovascular risk prediction. 61
33201052 2021
18
Enhanced external counterpulsation: A unique treatment for the "No-Option" refractory angina patient. 61
33410549 2021
19
Association Between Plasma ADAMTS-9 Levels and Severity of Coronary Artery Disease. 61
33307720 2021
20
[Meta-analysis of effect of Qishen Yiqi Dripping Pills combined with Western medicine on adverse cardiovascular events and quality of life after percutaneous coronary intervention]. 61
33787149 2021
21
Effects of breviscapine and C3435T MDR1 gene polymorphism on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers. 61
33256506 2021
22
Chinese medicine GeGen-DanShen extract protects from myocardial ischemic injury through promoting angiogenesis via up-regulation of VEGF/VEGFR2 signaling pathway. 61
33068653 2021
23
[Stable angina pectoris deserves better treatment]. 61
33720555 2021
24
Later bedtime is associated with angina pectoris in middle-aged and older adults: results from the Sleep Heart Health Study. 61
33465737 2021
25
Pre-operative assessment of patients undergoing spinal cord stimulation for refractory angina pectoris. 61
33734390 2021
26
Comparison of mitral annular displacement and global longitudinal strain imaging for predicting significant coronary atherosclerotic disease in patients of chronic stable angina pectoris. 61
33078275 2021
27
Assessment of coronary vasomotor responses to acetylcholine in German and Japanese patients with epicardial coronary spasm-more similarities than differences? 61
33044621 2021
28
Global identification and quantitative analysis of representative components of Xin-Nao-Kang Capsule, a traditional Chinese medicinal formula, by UHPLC-Q-TOF-MS and UHPLC-TQ-MS. 61
33706143 2021
29
Computed Tomography-Derived Fractional Flow Reserve in Patients With Chronic Coronary Syndrome: A Real-World Cohort Study. 61
33797438 2021
30
Coronary Collateral Flow Index Is Correlated With the Palmar Collateral Flow Index: Indicating Systemic Collateral Coherence in Individual Patients. 61
33730875 2021
31
Possible association between eating behaviors and cardiovascular disease in the general population: Analysis of a nationwide epidemiological database. 61
33581389 2021
32
Proteoglycan Remodeling Is Accelerated in Females with Angina Pectoris and Diffuse Myocardial Fibrosis: the iPOWER Study. 61
33649986 2021
33
Characteristics and Prognosis of Patients with Vasospastic Angina Diagnosed by a Provocation Test with Secondary Prevention Implantable Cardioverter Defibrillator. 61
33731515 2021
34
β-blocker use and risk of all-cause mortality in patients with coronary heart disease: effect modification by serum vitamin A. 61
33709106 2021
35
Associations between coronary heart disease and risk of cognitive impairment: A meta-analysis. 61
33742562 2021
36
Lipid Profile and Subsequent Cardiovascular Disease among Young Adults Aged < 50 Years. 61
33301771 2021
37
Estimating Long-Term Health Utility Scores and Expenditures for Cardiovascular Disease From the Medical Expenditure Panel Survey. 61
33761758 2021
38
Abdominal Aortic Intima-Media Thickness Predicts Coronary Artery Disease Severity in Patients With Stable Angina Pectoris: A Prospective Study. 61
33663258 2021
39
Relationship Between Systemic Immune-Inflammation Index (SII) and the Severity of Stable Coronary Artery Disease. 61
33685239 2021
40
Serum Bilirubin and Coronary Artery Disease: Intricate Relationship, Pathophysiology, and Recent Evidence. 61
31350011 2021
41
Comparison of the outcomes of the prolonged antianginal therapy use in stable coronary artery disease patients according to the data of randomized and observational studies. 61
33665472 2021
42
Effect of coexistence of Chlamydia pneumoniae and increased epicardial fat thickness on coronary artery disease. 61
33755966 2021
43
Added value of computed tomography fractional flow reserve in the diagnosis of coronary artery disease. 61
33762686 2021
44
Comparison of efficacy and safety of complementary and alternative therapies for coronary heart disease complicated with anxiety or depression disorder: A protocol for Bayesian network meta-analysis. 61
33761669 2021
45
Di'ao Xinxuekang: Therapeutic Potential in Cardiovascular Diseases. 61
33538685 2021
46
Age-Related Trajectories of Cardiovascular Risk and Use of Aspirin and Statin Among U.S. Adults Aged 50 or Older, 2011-2018. 61
33598936 2021
47
CD100 modulates cytotoxicity of CD8+ T cells in patients with acute myocardial infarction. 61
33593275 2021
48
Analyzing Spinal Cord Stimulator Explants in Refractory Angina Pectoris Patients. 61
33624809 2021
49
[Network Meta-analysis of Chinese patent medicine in treatment of unstable angina pectoris]. 61
33645038 2021
50
Predictors of treatment benefits after enhanced external counterpulsation in patients with refractory angina pectoris. 61
33400292 2021

Variations for Angina Pectoris

Expression for Angina Pectoris

LifeMap Discovery
Genes differentially expressed in tissues of Angina Pectoris patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 EGR3 early growth response 3 Blood + 4.04 0.001
Search GEO for disease gene expression data for Angina Pectoris.

Pathways for Angina Pectoris

Pathways related to Angina Pectoris according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.15 TNNI3 NPPB NOS3 INS IL6 ADIPOQ
2
Show member pathways
13 NOS3 KNG1 IL6 ICAM1 APOA1 ACE
3
Show member pathways
12.3 TNNI3 NPPB NOS3 KNG1 INS
4
Show member pathways
12.03 TNNI3 IL6 EDN1 ACE
5 11.88 PLAT NOS3 ICAM1 EDN1
6 11.75 PLAT INS IL6
7 11.71 NOS3 INS IL6 EDN1
8
Show member pathways
11.69 PIK3C2A INS ADIPOQ
9 11.6 TNNI3 INS IL6 ADIPOQ
10
Show member pathways
11.59 NOS3 KNG1 ACE
11
Show member pathways
11.43 PLAT INS IL6 ICAM1 CRP APOA1
12 11.35 NOS3 IL6 ICAM1 F3 EDN1
13 11.24 PLAT KNG1 IL6 ICAM1
14 11.02 KNG1 IL6 ICAM1 APOA1
15 10.4 NOS3 MB

GO Terms for Angina Pectoris

Cellular components related to Angina Pectoris according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.72 PLAT ICAM1 F3 APOA1 ADIPOQ
2 extracellular region GO:0005576 9.7 PLAT NPPB KNG1 INS IL6 F3
3 collagen-containing extracellular matrix GO:0062023 9.63 PLAT KNG1 ICAM1 F3 APOA1 ADIPOQ
4 endoplasmic reticulum lumen GO:0005788 9.56 KNG1 INS IL6 APOA1
5 extracellular space GO:0005615 9.4 PLAT NPPB KNG1 INS IL6 ICAM1

Biological processes related to Angina Pectoris according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.92 NOS3 INS IL6 F3 CRP
2 response to drug GO:0042493 9.9 ICAM1 EDN1 APOA1 ADIPOQ
3 cellular protein metabolic process GO:0044267 9.8 KNG1 INS IL6 APOA1
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.76 IL6 ICAM1 ADIPOQ
5 response to hypoxia GO:0001666 9.67 PLAT ICAM1 EDN1 ADIPOQ
6 cellular response to drug GO:0035690 9.65 HTR1B EDN1 ADIPOQ
7 positive regulation of interleukin-8 production GO:0032757 9.63 IL6 F3 ADIPOQ
8 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.62 IL6 ICAM1
9 positive regulation of renal sodium excretion GO:0035815 9.62 NPPB EDN1
10 positive regulation of urine volume GO:0035810 9.61 NPPB EDN1
11 negative regulation of blood coagulation GO:0030195 9.61 KNG1 EDN1
12 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.59 CRP ADIPOQ
13 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.58 APOA1 ADIPOQ
14 response to activity GO:0014823 9.58 IL6 EDN1 ADIPOQ
15 negative regulation of hormone secretion GO:0046888 9.57 EDN1 ADIPOQ
16 neutrophil mediated immunity GO:0002446 9.56 IL6 ACE
17 cellular response to alkaloid GO:0071312 9.55 ICAM1 HTR1B
18 negative regulation of lipid storage GO:0010888 9.54 IL6 CRP
19 body fluid secretion GO:0007589 9.51 NPPB EDN1
20 acute-phase response GO:0006953 9.5 INS IL6 CRP
21 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.43 NOS3 EDN1
22 negative regulation of proteolysis GO:0045861 9.43 PLAT KNG1 INS
23 regulation of blood vessel diameter GO:0097746 9.33 NPPB NOS3 ACE
24 vasoconstriction GO:0042310 9.13 HTR1B EDN1 CRP
25 regulation of blood pressure GO:0008217 8.92 NPPB NOS3 EDN1 ACE

Molecular functions related to Angina Pectoris according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.26 NPPB INS EDN1 ADIPOQ
2 signaling receptor binding GO:0005102 9.1 PLAT NPPB KNG1 EDN1 APOA1 ADIPOQ

Sources for Angina Pectoris

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....